



Brussels, 8.12.2020  
COM(2020) 659 final/2

ANNEX

COM(2020) 659 final of 16.10.2020 downgraded on 8.12.2020.

**ANNEX**

**to the**

**Proposal for a Council Decision**

**on the position to be taken, on behalf of the European Union, in the reconvened sixty-third session of the Commission on Narcotic Drugs on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971**

## ANNEX

Position to be taken by the Member States which are members of the Commission on Narcotic Drugs, acting jointly, in the interest of the Union during the reconvened sixty-third session of the Commission on Narcotic Drugs on 3 and 4 December 2020 regarding changes in the scope of control of substances:

- (1) cannabis and cannabis resin are to be deleted from Schedule IV of the Convention on Narcotic Drugs<sup>1</sup>;
- (2) dronabinol (*delta*-9-tetrahydrocannabinol) is to be added to Schedule I of the Convention on Narcotic Drugs and, if this recommendation is adopted, to be deleted from Schedule II of the Convention on Psychotropic Substances;
- (3) tetrahydrocannabinol (isomers of *delta*-9-tetrahydrocannabinol) is to be added to Schedule I of the Convention on Narcotic Drugs, subject to the CND's adoption of the recommendation to add dronabinol and its stereoisomers (*delta*-9-tetrahydrocannabinol) to Schedule I of the Convention on Narcotic Drugs, and, if this recommendation is adopted, is to be deleted from Schedule I of the Convention on Psychotropic Substances;
- (4) the term 'extracts and tinctures' is to be deleted from Schedule I of the Convention on Narcotic Drugs;
- (5) the footnote reading "*Preparations containing predominantly cannabidiol and not more than 0.2 percent of delta-9-tetrahydrocannabinol are not under international control*" shall not be added to the entry for cannabis and cannabis resin in Schedule I of the Convention on Narcotic Drugs; the WHO is invited to urgently propose a revised recommendation with a view to decide the appropriate level of international control for cannabidiol, including the possibility of exempting it from such control;
- (6) preparations produced either by chemical synthesis or as preparation of cannabis, that are compounded as pharmaceutical preparations with one or more other ingredients and in such a way that *delta*-9-tetrahydrocannabinol (dronabinol) cannot be recovered by readily available means or in a yield which would constitute a risk to public health shall not be added to Schedule III of the Convention on Narcotic Drugs.

In order to ensure coherence of the scheduling and to avoid the risk that a substance could be scheduled under the Convention on Narcotic Drugs as well as under the Convention on Psychotropic Substances, Member States can accept a joint vote on the recommendations concerning dronabinol and tetrahydrocannabinol.

---

<sup>1</sup> They continue to be listed in Schedule I of that Convention.